NEW YORK (Reuters Health) – For patients undergoing coronary artery bypass surgery, discontinuing chronic aspirin therapy at least 6 days before or within 5 days of surgery has…
NEW YORK (Reuters Health) – In patients with stage 1 and 2 hypertension, the experimental angiotensin receptor blocker (ARB) azilsartan medoxomil lowers blood pressure better than maximal doses…
NEW YORK (Reuters Health) – An analysis of “real-life” data from a French myocardial infarction (MI) registry fails to show any clinically relevant interaction between clopidogrel and proton…
NEW YORK (Reuters Health) – Suppressive therapy with corticosteroids and antihistamines is effective for managing clopidogrel hypersensitivity in the majority of cases, allowing antiplatelet therapy to continue uninterrupted,…
NEW YORK (Reuters Health) – A new study questions the “universal definition” of percutaneous coronary intervention (PCI)-related myocardial infarction (MI type 4a) — an increase of the biomarkers…
NEW YORK (Reuters Health) – The combination of fibrate and statin therapy is a safe and efficacious treatment option for women with multiple lipid abnormalities, a multicenter team…
NEW YORK (Reuters Health) – Atrial flutter seen in patients in the emergency department (ED) resolves more often with electrical cardioversion than with antiarrhythmic drug treatment, and long-term…
NEW YORK (Reuters Health) – Cardiac resynchronization therapy added to optimal medical therapy or in addition to an implantable cardioverter defibrillator (ICD) reduces mortality significantly in mild to…
NEW YORK (Reuters Health) – The selective sinoatrial I-f current inhibitor ivabradine lowers heart rate in patients with stable coronary artery disease and impaired left ventricular systolic function…
NEW YORK (Reuters Health) – Warfarin dosing based on genotype-stratified tables is more accurate than empiric dosing, but not as good as estimates derived from formal pharmacogenetic algorithms,…